Skip to main content

Anaptysbio, Inc 8-K, filed Nov 12, 2026

Anaptysbio, Inc (ANAB)

8-K 2026-11-12 For: 2026-11-12
View Original
Added on November 13, 2026

About this 8-K

Anaptysbio, Inc filed this 8-K on November 12, 2026.

AnaptysBio reported Jemperli global net sales of $1.0 billion (£753 million) through September 30, 2026, up 29% year-over-year, and U.S. approval in stage II and III MSI-H/dMMR locally advanced rectal cancer. A GSK and Tesaro judgment is anticipated in calendar Q4 2026 or Q1 2027. AI summary

Items reported

  • Item 2.02: Financial results
  • Item 9.01: Financial statements and exhibits